Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials

BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer associated with a poor prognosis. Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor, a mediator of tumor angiogenesis. Bevacizumab is currently under investigation as treatment for HCC. We performed a syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Ping, Hu, Jin-hua, Cheng, Zhi-gang, Liu, Zhe-feng, Wang, Jin-liang, Jiao, Shun-chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526612/
https://www.ncbi.nlm.nih.gov/pubmed/23284624
http://dx.doi.org/10.1371/journal.pone.0049717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526612/
https://www.ncbi.nlm.nih.gov/pubmed/23284624
http://dx.doi.org/10.1371/journal.pone.0049717

Ejemplares similares